Toxicological screening in the Amsterdam acute setting becomes more relevant if the standard panel of the drugs-of-abuse point-of-care test is expanded with GHB and ketamine.

van der Schaar, J A J; Attema-de Jonge, M E; Gresnigt, F M J; Franssen, E J F

van der Schaar, J A J; Attema-de Jonge, M E; Gresnigt, F M J; Franssen, E J F.

Afiliación

van der Schaar JAJ; Department of Clinical Pharmacy, OLVG, Amsterdam, The Netherlands.
Attema-de Jonge ME; Department of Clinical Pharmacy, OLVG, Amsterdam, The Netherlands.
Gresnigt FMJ; Emergency Department, OLVG, Amsterdam, The Netherlands.
Franssen EJF; Department of Clinical Pharmacy, OLVG, Amsterdam, The Netherlands.

Toxicol Rep ; 7: 539-546, 2020.

Article en En | MEDLINE | ID: mdl-32368504

Palabras clave

Drugs-of-abuse; Gamma-hydroxybutyric acid (GHB); Ketamine; Point-of-care test; Toxicological screening

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Screening_studies Idioma: En Revista: Toxicol Rep Año: 2020 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google